
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares highlights the substantial impact of type 2 inflammatory diseases on the quality of life of patients and their caregivers.
Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.
Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.

Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation
Hear Dr. Evan Dellon outline the benefits of maintenance therapy in EoE and the importance of an individualized treatment approach for each patient.

Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.
Experts Prof. Ingrid Terreehorst and Prof. Arjan Bredenoord discuss the allergist’s perspective on identifying and management of patients with EoE.

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in patients with asthma.
Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.